NCT07626151 Electric Cardiometry-Guided Standard Versus Restricted Fluid Therapy In Robotic Prostaectomy
| NCT ID | NCT07626151 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nazmy Edward Seif |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-06-05 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2026-06-05 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Fluid therapy during surgery is an important factor that is related to long term mortality and morbidity and it's directly related to tissue perfusion as well. The main target in any surgery is what is the optimum fluid therapy to maintain the tissue perfusion and the precise balance between hazardous effects of hypervolemia that may cause delayed wound healing due to surgical anastomosis disruption or being hypovolemic that may cause tissue ischemia as acute kidney injury. Fluid management guidance changed from static methods like central venous pressure into dynamic methods like pulse pressure variation (PPV) and stroke volume variation (SVV), which are now the most famous dynamic measures. Electrical cardiometry is a non-invasive cardiac output monitor which uses electrical cardiometry, now a commonly used device, to measure SVV which can be used to guide fluid therapy during surgeries. Now robotic assisted surgery is a common method in preforming many surgeries especially urological, since it's associated with numerous desirable outcomes including shorter post-operative stay and faster return to preoperative function. With considerations related to severe Trendelenburg position and increased intra-abdominal pressure due to pneumo-peritoneum, robotic assisted surgeries are associated with many challenges in anesthesia especially the fluid therapy. Fluid therapy in robotic surgeries is an area with growing research focus that need further exploration while there are established guidelines for fluid management in traditional surgeries, the optimal protocols for robotic surgeries are less well defined, needing more research. We aim at this study to investigate the impact of liberal versus restricted fluid intake on the tissue perfusion reflected by serum lactate \& creatinine clearance, while guiding therapy through electrical cardiometry, to reach optimum fluid protocol in prostatic robotic surgeries.
Eligibility Criteria
Inclusion Criteria: * Male patient undergoing robotic assisted prostatectomy * ASA I-III Exclusion Criteria: * ASA score more than III * BMI more than 40 * Severe renal disease (GFR between 15 and 29) * Previous renal surgery. * Decompensated cardiac disease (NYHA class 3 or 4)
Contact & Investigator
Ashgan R Aly, M.D.
STUDY CHAIR
Kasr Al-Ainy Hospital, Faculty of Medicine, Cairo University
Frequently Asked Questions
Who can join the NCT07626151 clinical trial?
This trial is open to male participants only, aged 40 Years or older, up to 80 Years, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07626151 currently recruiting?
Yes, NCT07626151 is actively recruiting participants. Contact the research team at mandamembo0@gmail.com for enrollment information.
Where is the NCT07626151 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07626151 clinical trial?
NCT07626151 is sponsored by Nazmy Edward Seif. The principal investigator is Ashgan R Aly, M.D. at Kasr Al-Ainy Hospital, Faculty of Medicine, Cairo University. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.